Compare Ralph Lauren Corp (RL) vs TransMedics Group Inc (TMDX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Ralph Lauren Corp vs TransMedics Group Inc — how do they compare? Ralph Lauren Corp trades at $340.2 (market cap $20.00B), while TransMedics Group Inc trades at $86.4 (market cap $3.00B). The key difference: Ralph Lauren Corp is far larger — about 6.7× TransMedics Group Inc's market cap, and Ralph Lauren Corp pays a 1.19% dividend while TransMedics Group Inc pays none. Which is the better fit depends on your goals.
| RL | TMDX | |
|---|---|---|
Market Cap | $20.00B | $3.00B |
Sector | Consumer Cyclical | Technology |
52-Week High | $414.25 | $150.42 |
52-Week Low | $302.89 | $61.99 |
Enterprise Value | $21.06B | $3.39B |
Dividend Yield | 1.19% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Ralph Lauren (RL) trades at $347.23, down 1.13% with bearish technical signals but strong fundamentals. The stock shows consistent earnings beats with Q2 2026 EPS of $4.59 exceeding expectations. Revenue growth accelerated to $7.08 billion in 2025 with improving profit margins of 11.76%. Analyst consensus remains strongly bullish with 66% buy ratings and a $456.50 price target representing 31% upside potential.
The investment case balances strong brand momentum and financial performance against technical weakness. Upside catalysts include luxury positioning strength and digital growth, while risks include premium valuation and market volatility. The stock presents a compelling opportunity for investors comfortable with near-term technical pressure given the fundamental strength and analyst optimism.
TransMedics Group (TMDX) trades at $88.27, down 1.9% on the day, with a bullish technical signal from moving averages but mixed earnings results. The company reported strong revenue growth to $605.49M in 2025, with a net income margin of 22.69%, though profitability is expected to moderate in 2026. Recent news highlights ongoing legal investigations into fiduciary duties alongside positive coverage of growth initiatives in kidney transplantation and European expansion.
The stock presents a growth opportunity with analyst consensus pointing to a $99.57 price target, but risks include margin pressure from heavy investments and legal uncertainties. Earnings misses in recent quarters and a projected decline in net income for 2026 warrant caution, though institutional interest remains with a bullish rating from 69% of analysts.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Ralph Lauren Corp
Founded by designer Ralph Lauren in 1967, Ralph Lauren Corp. designs, markets, and distributes lifestyle products in North America, Europe, and Asia. Its products include apparel, footwear, eyewear, jewelry, leather goods, home products, and fragrances. The company's brands include Ralph Lauren Collection, Polo Ralph Lauren, Lauren Ralph Lauren, and Double RL. Distribution channels for Ralph Lauren include wholesale (including department stores and specialty stores), retail (including company-owned retail stores and e-commerce), and licensing.
Read more on RL →About TransMedics Group Inc
TransMedics is a pioneering medical technology company that is disrupting the organ transplant market with its Organ Care System (OCS™). By replacing traditional cold storage with portable warm perfusion, the OCS maintains donor organs in a near-physiologic state, allowing for continuous assessment and optimization. Through its National OCS Program (NOP™), TransMedics provides an end-to-end clinical and logistics solution, including a dedicated aviation fleet, to maximize the utilization of donor organs and improve patient outcomes.
Read more on TMDX →
